<SEC-DOCUMENT>0001157523-21-001366.txt : 20211108
<SEC-HEADER>0001157523-21-001366.hdr.sgml : 20211108
<ACCEPTANCE-DATETIME>20211108161538
ACCESSION NUMBER:		0001157523-21-001366
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20211108
FILED AS OF DATE:		20211108
DATE AS OF CHANGE:		20211108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nanobiotix S.A.
		CENTRAL INDEX KEY:			0001760854
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39777
		FILM NUMBER:		211388142

	BUSINESS ADDRESS:	
		STREET 1:		60 RUE DE WATTIGNIES
		CITY:			PARIS
		STATE:			I0
		ZIP:			75012
		BUSINESS PHONE:		33140260470

	MAIL ADDRESS:	
		STREET 1:		60 RUE DE WATTIGNIES
		CITY:			PARIS
		STATE:			I0
		ZIP:			75012
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a52525426.htm
<DESCRIPTION>NANOBIOTIX S.A. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.6.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;">
  </font>
  <div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">FORM 6-K</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Report of Foreign Private Issuer</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">of the Securities Exchange Act of 1934</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; font-weight: bold;">Date of Report: 11/08/2021</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; font-weight: bold;">Commission File Number: 001-39777</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">Nanobiotix S.A.</div>
    <div style="text-align: center; font-weight: bold;">(Exact Name of Registrant as Specified in its Charter)</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; font-weight: bold;">60 Rue de Wattignies</div>
    <div style="text-align: center; font-weight: bold;">75012 Paris, France</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">(Address of principal executive office)</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center;">Form 20-F &#9746; Form 40-F &#9744;</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="font-weight: bold;"><u>EXHIBIT INDEX</u></div>
    <table cellspacing="0" cellpadding="0" border="0" id="zea1a904d49c645199f3b5d3ea6d24a9c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 8%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 92%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 8%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="font-weight: bold;">Exhibit</div>
          </td>
          <td nowrap="nowrap" style="width: 92%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="font-weight: bold;">Title</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 92%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>
        <tr>
          <td nowrap="nowrap" style="width: 8%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0);"><a href="a52525426ex99_1.htm">99.1</a></div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0);"><a href="a52525426ex99_1.htm">Press Release, dated November 08, 2021</a></div>
          </td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman',Times,serif; font-weight: 400;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
      thereunto duly authorized.</div>
    <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z3a44ec3c284b4cc097e7235269764101" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 4.15%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 3%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2" rowspan="1">
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;">PORTER NOVELLI</div>
            <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">(Agency)</div>
          </td>
          <td style="width: 24%; vertical-align: top;" colspan="1">&#160;</td>
          <td style="vertical-align: top;" colspan="2">
            <div style="color: #000000; font-weight: bold;">NANOBIOTIX S.A.</div>
            <div style="color: #000000;">(Registrant)</div>
          </td>
          <td style="vertical-align: top; width: 10%;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 4.15%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 3%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;" colspan="1">&#160;</td>
          <td style="width: 28%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 24%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;" colspan="1">&#160;</td>
          <td style="width: 3%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 28%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 10%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 4.15%; vertical-align: top; font-family: 'Times New Roman',Times,serif; padding-bottom: 2px;">&#160;</td>
          <td style="width: 3%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="1">By:<br>
          </td>
          <td style="width: 28%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Emily Papp<br>
            </div>
          </td>
          <td style="width: 24%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td style="width: 3%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div>By:</div>
          </td>
          <td style="width: 28%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div>/s/ Bart Van Rhijn</div>
            </div>
          </td>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 4.15%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1" colspan="1">&#160;</td>
          <td style="width: 28%; vertical-align: bottom;" rowspan="1">&#160;</td>
          <td style="width: 24%; vertical-align: bottom;" rowspan="1" colspan="1">&#160;</td>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
          <td style="width: 28%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 10%; vertical-align: top;" rowspan="1" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 4.15%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1" colspan="1">&#160;</td>
          <td style="width: 28%; vertical-align: bottom;" rowspan="1">&#160;</td>
          <td style="width: 24%; vertical-align: bottom;" rowspan="1" colspan="1">&#160;</td>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
          <td style="width: 28%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 10%; vertical-align: top;" rowspan="1" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 4.15%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1" colspan="1">&#160;</td>
          <td style="width: 28%; vertical-align: bottom;" rowspan="1">&#160;</td>
          <td style="width: 24%; vertical-align: bottom;" rowspan="1" colspan="1">&#160;</td>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
          <td style="width: 28%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 10%; vertical-align: top;" rowspan="1" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 4.15%; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" colspan="1">&#160;</td>
          <td style="width: 28%; vertical-align: bottom;">
            <div style="color: #000000;"><font style="font-family: 'Times New Roman',Times,serif;">Emily Papp</font></div>
          </td>
          <td style="width: 24%; vertical-align: bottom;" colspan="1">&#160;</td>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 28%; vertical-align: top;">
            <div style="color: #000000;"><font style="font-family: 'Times New Roman',Times,serif;">Bart Van Rhijn</font></div>
          </td>
          <td style="width: 10%; vertical-align: top;" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 4.15%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" colspan="1">&#160;</td>
          <td style="width: 28%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0);">Senior Account Executive</div>
          </td>
          <td style="width: 24%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="1">&#160;</td>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 28%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="color: rgb(0, 0, 0);">Chief Financial Officer</div>
          </td>
          <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" colspan="1">&#160;</td>
        </tr>

    </table>
    <div style="font-family: 'Times New Roman',Times,serif;"><br>
    </div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;">
  </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a52525426ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.6.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div><font style="font-weight: bold;"> <br>
    </font></div>
  <div>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company&#8217;s Share Capital</b> </h1>
      <div class="bw-release-subhead">
        <p style="text-align: center; list-style-position: inside;"><b> <b><i>In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorit&#233; des March&#233;s Financiers (French Financial Markets
                Authority)</i></b> </b></p>
      </div>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>PARIS--(BUSINESS WIRE)--November 8, 2021--Regulatory News: </p>
          <p> Nanobiotix (Paris:NANO) (NASDAQ:NBTX): </p>
          <p> Market: Euronext Paris / Nasdaq <br>
            Euronext Compartment: B <br>
            ISIN code: FR0011341205 <br>
            Nasdaq: NBTX <br>
            Bloomberg: NANO:FP <br>
            Reuters: NANO.PA <br>
            Website: www.nanobiotix.com </p>
          <table cellspacing="0" style="margin-bottom: 10px;margin-left: 0px; margin-right: auto; font-size: 10pt;" id="z5b00d759153f4fc195f01e7c65a75453">

              <tr>
                <td rowspan="2" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;text-align: center; list-style-position: inside;border-top: solid black 1pt;" colspan="1">
                  <p style="list-style-position: inside; margin-bottom: 0px; margin-top: 0px;"> <b>Date</b> </p>
                </td>
                <td rowspan="2" style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;text-align: center; list-style-position: inside;border-top: solid black 1pt;" colspan="1">
                  <p style="list-style-position: inside; margin-bottom: 0px; margin-top: 0px;"> <b>Number of Shares Outstanding</b> </p>
                  <p style="list-style-position: inside; margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="2" style="vertical-align: top;border-top: solid black 1pt;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;text-align: center; list-style-position: inside;" rowspan="1">
                  <p style="list-style-position: inside; margin-bottom: 0px; margin-top: 0px;"> <b>Total number of voting rights</b> </p>
                </td>
              </tr>
              <tr>
                <td style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;text-align: center; list-style-position: inside;" rowspan="1" colspan="1">
                  <p style="list-style-position: inside; margin-bottom: 0px; margin-top: 0px;"> <b>Total voting rights, gross <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></b> </p>
                  <p style="list-style-position: inside; margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;text-align: center; list-style-position: inside;" rowspan="1" colspan="1">
                  <p style="list-style-position: inside; margin-bottom: 0px; margin-top: 0px;"> <b>Total voting rights,</b> </p>
                  <p style="list-style-position: inside; margin-bottom: 0px; margin-top: 0px;"> <b>net <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></b> </p>
                </td>
              </tr>
              <tr>
                <td style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;text-align: center; list-style-position: inside;" rowspan="1" colspan="1">
                  <p style="list-style-position: inside; margin-bottom: 0px; margin-top: 0px;"> October 31, 2021&#160; </p>
                </td>
                <td style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: top;text-align: center; list-style-position: inside;" rowspan="1" colspan="1">
                  <p style="margin-bottom: 0px; margin-top: 0px; list-style-position: inside;"> 34,825,872 </p>
                </td>
                <td style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: top;text-align: center; list-style-position: inside;" rowspan="1" colspan="1">
                  <p style="margin-bottom: 0px; margin-top: 0px; list-style-position: inside;"> 36,003,389 </p>
                </td>
                <td style="border-bottom: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;padding-right: 0px;vertical-align: top;text-align: center; list-style-position: inside;" rowspan="1" colspan="1">
                  <p style="margin-bottom: 0px; margin-top: 0px; list-style-position: inside;"> 35,983,625 </p>
                </td>
              </tr>

          </table>
          <p> <i><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup> The total number of gross (or &#8220;theoretical&#8221;) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis
              of all shares to which voting rights are attached, including those for which voting rights have been suspended.</i> </p>
          <p> <i><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup> The total number of net (or &#8220;exercisable at a Shareholders&#8217; Meeting&#8221;) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the
              public is properly informed, in accordance with the AMF recommendation of July 17, 2007.</i> </p>
          <p style="text-align: center; list-style-position: inside;"> <i>***</i> </p>
          <p> <b>About NANOBIOTIX : </b>http://www.nanobiotix.com </p>
          <p> Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for
            humanity. The company&#8217;s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. </p>
          <p> Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany. Nanobiotix has been listed on the regulated market of Euronext in
            Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. </p>
          <p> Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The
            company's resources are primarily devoted to the development of its lead product candidate&#8211; NBTXR3 &#8212;which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients
            with soft tissue sarcoma under the brand name Hensify&#174;. </p>
          <p> For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter. </p>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> <i>Nanobiotix </i><br>
            <b>Nanobiotix Communications </b><br>
            <i>Brandon Owens </i><br>
            <i>VP, Communications </i><br>
            +1 (617) 852-4835 <br>
            contact@nanobiotix.com </p>
          <p> <b>Nanobiotix Investor Relations </b><br>
            <i>Kate McNeil </i><br>
            <i>SVP, Investor Relations </i><br>
            +1 (609) 678-7388 <br>
            investors@nanobiotix.com </p>
          <p> <i>Media Relations </i><br>
            France &#8211; <b>Ulysse Communication </b><br>
            Pierre-Louis Germain <br>
            + 33 (0) 6 64 79 97 51 <br>
            plgermain@ulysse-communication.com </p>
          <p> US &#8211; <b>Porter Novelli </b><br>
            Dan Childs <br>
            +1 (781) 888-5106 <br>
            dan.childs@porternovelli.com </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
